KR101073760B1 - Ｎ-（2-아미노페닐）-4-［ｎ-（피리딘-3-일）-메톡시카르보닐-아미노메틸］-벤즈아미드 （ｍｓ-275） 다형체 ｂ - Google Patents

Ｎ-（2-아미노페닐）-4-［ｎ-（피리딘-3-일）-메톡시카르보닐-아미노메틸］-벤즈아미드 （ｍｓ-275） 다형체 ｂ Download PDF

Info

Publication number
KR101073760B1
KR101073760B1 KR1020117007131A KR20117007131A KR101073760B1 KR 101073760 B1 KR101073760 B1 KR 101073760B1 KR 1020117007131 A KR1020117007131 A KR 1020117007131A KR 20117007131 A KR20117007131 A KR 20117007131A KR 101073760 B1 KR101073760 B1 KR 101073760B1
Authority
KR
South Korea
Prior art keywords
aminophenyl
benzamide
pyridin
polymorph
methoxycarbonylaminomethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117007131A
Other languages
English (en)
Korean (ko)
Other versions
KR20110038187A (ko
Inventor
마티아스 슈나이더
미카엘 고트프리트
옌스 가이슬러
가브리엘레 빈터
Original Assignee
바이엘 파마 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41133825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101073760(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 바이엘 파마 악티엔게젤샤프트 filed Critical 바이엘 파마 악티엔게젤샤프트
Publication of KR20110038187A publication Critical patent/KR20110038187A/ko
Application granted granted Critical
Publication of KR101073760B1 publication Critical patent/KR101073760B1/ko
Assigned to 바이엘 인텔렉쳐 프로퍼티 게엠베하 reassignment 바이엘 인텔렉쳐 프로퍼티 게엠베하 권리의 전부이전등록 Assignors: 바이엘 파마 악티엔게젤샤프트
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020117007131A 2008-08-29 2009-08-27 Ｎ-（2-아미노페닐）-4-［ｎ-（피리딘-3-일）-메톡시카르보닐-아미노메틸］-벤즈아미드 （ｍｓ-275） 다형체 ｂ Active KR101073760B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9304608P 2008-08-29 2008-08-29
US61/093,046 2008-08-29
EP08163274.7 2008-08-29
EP08163274 2008-08-29
PCT/EP2009/006381 WO2010022988A1 (en) 2008-08-29 2009-08-27 N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275)polymorph b

Publications (2)

Publication Number Publication Date
KR20110038187A KR20110038187A (ko) 2011-04-13
KR101073760B1 true KR101073760B1 (ko) 2011-10-13

Family

ID=41133825

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117007131A Active KR101073760B1 (ko) 2008-08-29 2009-08-27 Ｎ-（2-아미노페닐）-4-［ｎ-（피리딘-3-일）-메톡시카르보닐-아미노메틸］-벤즈아미드 （ｍｓ-275） 다형체 ｂ

Country Status (35)

Country Link
US (2) US7973166B2 (https=)
EP (1) EP2350005B1 (https=)
JP (1) JP4921616B2 (https=)
KR (1) KR101073760B1 (https=)
CN (1) CN102137846B (https=)
AR (1) AR073226A1 (https=)
AT (1) ATE538094T1 (https=)
AU (1) AU2009286982C1 (https=)
BR (1) BRPI0918580B8 (https=)
CA (1) CA2735294C (https=)
CO (1) CO6351736A2 (https=)
CR (2) CR20110107A (https=)
CY (1) CY1112645T1 (https=)
DK (1) DK2350005T3 (https=)
DO (1) DOP2011000064A (https=)
EA (1) EA016811B1 (https=)
EC (1) ECSP11010849A (https=)
ES (1) ES2378640T3 (https=)
HN (1) HN2011000609A (https=)
HR (1) HRP20120183T8 (https=)
IL (1) IL211276A (https=)
MA (1) MA32610B1 (https=)
MX (1) MX2011002248A (https=)
MY (1) MY149058A (https=)
NZ (1) NZ591387A (https=)
PE (2) PE20141062A1 (https=)
PL (1) PL2350005T3 (https=)
PT (1) PT2350005E (https=)
RS (1) RS52164B (https=)
SI (1) SI2350005T1 (https=)
SM (1) SMT201200026B (https=)
SV (1) SV2011003846A (https=)
TW (1) TWI427062B (https=)
WO (1) WO2010022988A1 (https=)
ZA (1) ZA201102285B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141062A1 (es) 2008-08-29 2014-09-19 Bayer Ip Gmbh Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
FR2977492B1 (fr) * 2011-07-04 2013-07-05 Servier Lab Nouvelle association entre le n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl) benzofuran-2-ylcarbonylamino]ethoxy}benzamide et le folfox
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
EP3168210A1 (en) 2015-11-13 2017-05-17 Sandoz Ag Crystalline forms of entinostat
WO2017216761A1 (en) * 2016-06-17 2017-12-21 Dr. Reddy's Laboratories Limited Solid forms of entinostat
US11208382B2 (en) 2017-07-28 2021-12-28 Hangzhou Solipharma Co., Ltd. Entinostat-containing compound, crystal form of compound thereof, and preparation method therefor and pharmaceutical composition thereof
JP2024517919A (ja) 2021-05-10 2024-04-23 マクファーラン スミス リミテッド エンチノスタットの新規形態

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001131130A (ja) 1999-11-09 2001-05-15 Mitsui Chemicals Inc モノアシルフェニレンジアミン誘導体の精製法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
JP4030683B2 (ja) * 1998-07-24 2008-01-09 三井化学株式会社 ベンズアミド誘導体の合成法
US6320078B1 (en) * 1998-07-24 2001-11-20 Mitsui Chemicals, Inc. Method of producing benzamide derivatives
JP2001064177A (ja) * 1999-08-16 2001-03-13 Schering Ag ベンズアミド誘導体を有効成分とする製剤
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
PE20141062A1 (es) 2008-08-29 2014-09-19 Bayer Ip Gmbh Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001131130A (ja) 1999-11-09 2001-05-15 Mitsui Chemicals Inc モノアシルフェニレンジアミン誘導体の精製法

Also Published As

Publication number Publication date
CY1112645T1 (el) 2016-02-10
MX2011002248A (es) 2011-03-29
PL2350005T3 (pl) 2012-05-31
AR073226A1 (es) 2010-10-20
KR20110038187A (ko) 2011-04-13
CO6351736A2 (es) 2011-12-20
USRE45499E1 (en) 2015-04-28
HRP20120183T8 (en) 2012-11-30
BRPI0918580A8 (pt) 2017-07-11
TW201014820A (en) 2010-04-16
RS52164B (sr) 2012-08-31
CR20110107A (es) 2011-04-28
US7973166B2 (en) 2011-07-05
SV2011003846A (es) 2011-07-27
SMT201200026B (it) 2012-07-10
US20100056585A1 (en) 2010-03-04
AU2009286982C1 (en) 2012-04-26
HK1160107A1 (en) 2012-08-10
HN2011000609A (es) 2014-09-29
BRPI0918580B8 (pt) 2021-05-25
ES2378640T3 (es) 2012-04-16
DK2350005T3 (da) 2012-03-19
CN102137846A (zh) 2011-07-27
PE20141062A1 (es) 2014-09-19
HRP20120183T1 (hr) 2012-03-31
SI2350005T1 (sl) 2012-03-30
CA2735294A1 (en) 2010-03-04
CR20160465A (es) 2016-12-06
EA201100354A1 (ru) 2011-10-31
NZ591387A (en) 2012-03-30
PT2350005E (pt) 2012-03-12
JP4921616B2 (ja) 2012-04-25
EP2350005B1 (en) 2011-12-21
AU2009286982A1 (en) 2010-03-04
JP2012500819A (ja) 2012-01-12
EP2350005A1 (en) 2011-08-03
IL211276A0 (en) 2011-04-28
MY149058A (en) 2013-07-15
PE20110677A1 (es) 2011-09-16
IL211276A (en) 2014-07-31
CA2735294C (en) 2013-10-15
ZA201102285B (en) 2011-12-28
AU2009286982B2 (en) 2011-06-23
WO2010022988A1 (en) 2010-03-04
BRPI0918580B1 (pt) 2020-11-24
ATE538094T1 (de) 2012-01-15
DOP2011000064A (es) 2011-03-31
BRPI0918580A2 (pt) 2015-12-01
CN102137846B (zh) 2014-04-23
TWI427062B (zh) 2014-02-21
MA32610B1 (fr) 2011-09-01
EA016811B1 (ru) 2012-07-30
ECSP11010849A (es) 2011-03-31

Similar Documents

Publication Publication Date Title
KR101073760B1 (ko) Ｎ-（2-아미노페닐）-4-［ｎ-（피리딘-3-일）-메톡시카르보닐-아미노메틸］-벤즈아미드 （ｍｓ-275） 다형체 ｂ
TWI549954B (zh) 經取代之２，３－二氫咪唑并［１，２－ｃ］喹唑啉鹽
JP5346293B2 (ja) ４−［４−（｛［４−クロロ−３−（トリフルオロメチル）フェニル）］カルバモイル｝アミノ）−３−フルオロフェノキシ］−ｎ−メチルピリジン−２−カルボキサミド一水和物
RU2292344C2 (ru) Производные пиридилцианогуанидинов и фармацевтическая композиция на их основе
KR20130099117A (ko) 치환된 ｎ-(2-아릴아미노)아릴 설폰아미드 함유 배합물
KR101010871B1 (ko) 시아노구아니딘 프로드럭
HK1160107B (en) N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275)polymorph b
GB2462893A (en) Preparation of and compositions comprising N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxycarbonylaminomethyl]-benzamide (MS-275) polymorph B
NZ616198B2 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
HK1136287B (en) 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl)]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide monohydrate

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
PA0105 International application

Patent event date: 20110328

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110328

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20110328

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110601

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20110919

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20111007

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20111007

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
J202 Request for trial for correction [limitation]
PJ0202 Trial for correction

Comment text: Request for Trial

Patent event date: 20120517

Patent event code: PJ02022R01D

Comment text: Registration of Establishment

Patent event date: 20111007

Patent event code: PJ02021E01I

Appeal kind category: Correction

Decision date: 20120822

Request date: 20120517

Appeal identifier: 2012105000049

J301 Trial decision

Free format text: TRIAL DECISION FOR CORRECTION REQUESTED 20120517

Effective date: 20120822

Free format text: TRIAL NUMBER: 2012105000049; TRIAL DECISION FOR CORRECTION REQUESTED 20120517

Effective date: 20120822

PJ1301 Trial decision

Patent event code: PJ13011S03D

Patent event date: 20120822

Comment text: Trial Decision on Correction (Patent, Utility Model)

Appeal kind category: Correction

Request date: 20120517

Decision date: 20120822

Appeal identifier: 2012105000049

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

Publication date: 20120831

FPAY Annual fee payment

Payment date: 20140930

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20140930

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20151001

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20151001

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20160929

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20160929

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20170929

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20170929

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20181001

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20181001

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20190927

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20190927

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20201005

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20201005

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20211005

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20211005

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20220929

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20220929

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20231004

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20240927

Start annual number: 14

End annual number: 14